Paper8709686
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
Lancet, 1996. Cited by 266 papers, by iCite.
Cite this record
ConductScience Library. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Papers, record 8709686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8709686
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
- PubMed
- Publication types
- Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Didanosine | Major topic |
| HIV Infections | Major topic |
| Zalcitabine | Major topic |
| Zidovudine | Major topic |
| Adolescent | |
| Adult | |
| CD4 Lymphocyte Count | |
| Disease Progression | |
| Double-Blind Method | |
| Drug Therapy, Combination | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Survival Analysis |
Source PubMed
Comments and corrections4
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 8709681 | Delta in the real world. | https://conductscience.org/library/papers/8709681 | PubMed |
| Comment in | 8898046 | The Delta trial. | https://conductscience.org/library/papers/8898046 | PubMed |
| Comment in | 8898047 | The Delta trial. | https://conductscience.org/library/papers/8898047 | PubMed |
| Comment in | 11556343 | Liver failure after long-term nucleoside antiretroviral therapy. | https://conductscience.org/library/papers/11556343 | PubMed |
Cited by54
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 266 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36796006 | [Medical Care of people living with HIV in the Instituto Mexicano del Seguro Social]. | Rev Med Inst Mex Seguro Soc | 2022 | https://conductscience.org/library/papers/36796006 | PubMed |
| 36130204 | New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates? | FEMS Microbiol Rev | 2023 | https://conductscience.org/library/papers/36130204 | PubMed |
| 35491570 | The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir. | Antivir Ther | 2022 | https://conductscience.org/library/papers/35491570 | PubMed |
| 35399147 | Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort. | Infect Dis Ther | 2022 | https://conductscience.org/library/papers/35399147 | PubMed |
| 34726308 | Marine mollusc extracts-Potential source of SARS-CoV-2 antivirals. | Rev Med Virol | 2022 | https://conductscience.org/library/papers/34726308 | PubMed |
| 32854292 | Promoting Undetectable Equals Untransmittable in Sub-Saharan Africa: Implication for Clinical Practice and ART Adherence. | Int J Environ Res Public Health | 2020 | https://conductscience.org/library/papers/32854292 | PubMed |
| 32659363 | Achieving effective informed oversight by DMCs in COVID clinical trials. | J Clin Epidemiol | 2020 | https://conductscience.org/library/papers/32659363 | PubMed |
| 29860311 | PAK1 regulates ATXN1 levels providing an opportunity to modify its toxicity in spinocerebellar ataxia type 1. | Hum Mol Genet | 2018 | https://conductscience.org/library/papers/29860311 | PubMed |
| 29340087 | Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug. | Oncotarget | 2017 | https://conductscience.org/library/papers/29340087 | PubMed |
| 29339063 | Evolution of Intravitreal Therapy for Retinal Diseases-From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture. | Am J Ophthalmol | 2018 | https://conductscience.org/library/papers/29339063 | PubMed |
| 28775605 | THERAPY AND PROPHYLAXIS IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION. | Med J Armed Forces India | 1999 | https://conductscience.org/library/papers/28775605 | PubMed |
| 22996358 | [Morbidity and mortality in HIV infection]. | Internist (Berl) | 2012 | https://conductscience.org/library/papers/22996358 | PubMed |
| 21694884 | New approaches in the management of chronic hepatitis B: role of tenofovir. | Infect Drug Resist | 2009 | https://conductscience.org/library/papers/21694884 | PubMed |
| 21182347 | Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. | Pharmacoeconomics | 2010 | https://conductscience.org/library/papers/21182347 | PubMed |
| 20624077 | Incident neuropathy in HIV-infected patients on HAART. | AIDS Res Hum Retroviruses | 2010 | https://conductscience.org/library/papers/20624077 | PubMed |
| 19825136 | Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future. | J Int AIDS Soc | 2006 | https://conductscience.org/library/papers/19825136 | PubMed |
| 19361855 | Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. | Lancet | 2009 | https://conductscience.org/library/papers/19361855 | PubMed |
| 18472979 | The renaissance of fixed dose combinations: Combivir. | Ther Clin Risk Manag | 2007 | https://conductscience.org/library/papers/18472979 | PubMed |
| 18004087 | Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. | Am J Med Sci | 2007 | https://conductscience.org/library/papers/18004087 | PubMed |
| 17053925 | [Antiviral treatment regimens]. | Hautarzt | 2006 | https://conductscience.org/library/papers/17053925 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Authors
- Grants
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8709686
GET https://conductscience.org/api/papers/v1/8709686/cited_by?page=2